- Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Oncotarget (2015-01-13)
Minran Zhou, Jiping Zeng, Xiaoming Wang, Xiangyu Wang, Tao Huang, Yue Fu, Ting Sun, Jihui Jia, Chunyan Chen
PMID25575817
ABSTRACT
Chronic myeloid leukemia in the blastic phase (CML-BP) responds poorly to clinical treatments and is usually fatal. In this study, we found that the histone H3 lysine 4 (H3K4) demethylase RBP2 (also called JARID1A and KDM5A) is underexpressed in CML-BP. The RBP2 histone demethylase stimulates leukemia cell differentiation and inhibits cell proliferation. We identified miR-21 was directly downregulated by RBP2 and found that miR-21 downregulated PDCD4 expression in leukemia cells. By binding to miR-21 promoter and by demethylating of trimethylated H3K4 at the miR-21 locus, RBP2 downregulated miR-21 expression. This in turn activated PDCD4. In conclusion, RBP2 epigenetically downregulated miR-21 in blast transformation of CML.
MATERIALS
Product Number
Brand
Product Description
Tretinoin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dimethyl sulfoxide, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
8-Octanoyloxypyrene-1,3,6-trisulfonic acid trisodium salt, suitable for fluorescence, ≥90% (HPCE)
Sigma-Aldrich
Dimethyl sulfoxide, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Dimethyl sulfoxide, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max™, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%